Global Liquid Biopsy Market is expected to reach USD XX Million by 2027 with CAGR of XX % from USD 877.62 Million in 2019. The report includes the analysis of impact of COVID-19 lock-down on the revenue of market leaders, followers, and disrupters. Since lock down was implemented differently in different regions and countries, impact of same is also different by regions and segments. The report has covered the current short term and long term impact on the market, same will help decision makers to prepare the outline for short term and long term strategies for companies by region. A liquid biopsy, also known as fluid biopsy or fluid phase biopsy is a simple and non-invasive alternative to surgical biopsies which enables doctors to discover a wide range of information about a tumour through samples like a blood sample, urine sample, Plasma, and other bio fluids. This is a comprehensive report on the Global Liquid Biopsy Market Analysis on the basis of cancer types, products, Technology/circulating biomarkers, Sample Types, and the end-users and Global Forecasts (2019 -2026). Some of the factors majorly involved in the growth of this market include increasing and persisting widespread presence of cancer, increasing preference for non-invasive procedures for liquid biopsy by oncologists, and availability of funding for liquid biopsy research & development. From the clinical application segment, the therapy selection segment is anticipated to account for the largest share of the liquid biopsy market in 2019 owing to potential benefits offered by liquid biopsy in therapy selections. The assay kits segment from product segment is anticipated to hold a larger share of the overall Global Liquid Biopsy Market owing to surge in basic research and commercial applications, growing need for reliable and specific assays, and rise in demand for liquid biopsy tests. Global Liquid Biopsy Market for cancer application segment is anticipated to grow at the highest CAGR during the forecast period. From the end user segment, liquid biopsy market for reference laboratories segment is expected to account for the larger share of the Global Liquid Biopsy Market, owing to increased number of liquid biopsy test samples outsourced to reference laboratories. Among the geographical regions, North America is anticipated to lead the market in terms of revenue. This growth can be attributed to easy accessibility and high adoption of advanced diagnostic technologies among healthcare professionals. However, APAC is expected to witness the highest CAGR between 2017 and 2024. The growing focus of global life science companies in this region, rising penetration of cutting-edge diagnostic technologies, rising disposable incomes in the middle-class populations' infrastructural developments, and government initiatives to increase awareness about genome-based diagnostic procedures are the major factors propelling the growth of liquid biopsy market in this region. Key Highlights: • Global Liquid Biopsy Market report is a result of detailed qualitative and quantitative analysis of the current market trends and forecast of global opportunities and growth. • In-depth analysis of the industry on the basis of market segments, market dynamics, market size, competition & companies involved value chain • Global Liquid Biopsy Market report would help stakeholders understand their competitors better and gain more insights to enhance their position in the business • Market estimations based on a comprehensive analysis of the key factors in the industry. • The complete analysis of factors that play the major role in changing the market scenario, prospective opportunities, market shares, growth strategies, and business optimization methodologies along with the mentioning of major companies is specified • Provides detailed information regarding the major factors influencing the growth of the Liquid Biopsy Market (drivers, restraints, opportunities, and challenges) • Analysis based on geography to assess the opportunities of regional markets and understand and plan the business strategy. Research Methodology: The objective of the analysis is to estimate the market size of the Global Liquid Biopsy Market for 2017 and project its trend in demands till 2024 with qualitative and quantitative analysis of cloud testing in the cloud computing environment of the Global Liquid Biopsy Market. Our experts’ team has studied various industry reports, directories, and journals, referred data and information available with various sources and associations to collect relevant information and carry out necessary analysis to put it in concatenated and segmented format to make the most use out of it. Primary research has been carried out; also, various experts from industries and suppliers from around the globe have given their inputs in order to make the analysis more accurate.
Key Players in Global Liquid Biopsy Market are:The major key players that influence the growth of the Liquid Biopsy Market globally are as listed: • Qiagen N.V. • Roche Diagnostics • Bio-Rad Laboratories Inc. • Myriad Genetics, Inc. • Menarini Silicon Biosystems • Genomic Health, Inc. • Thermo Fisher Scientific Inc. • Illumina, Inc. • Biocept, Inc. • Trovagene, Inc. • Guardant Health, Inc. • RainDance Technologies, Inc. • MDxHealth SA • F. Hoffmann-La Roche AG • Myriad Genetics • Janssen Diagnostics • GRAIL • Foundation Medicine Key Target Audience: • Liquid biopsy system manufacturers, suppliers, and distributors • Research Centres and Institutes • Physicians and surgeons • Healthcare service providers and clinical research organizations • Market research and consulting firms • Reference Laboratories • Hospitals and Physician Laboratories • Research institutes and organizations • Government bodies, venture capitalists, and private equity firms • Market research and consulting firms
The scope of the Report:The report breaks down the Analysis and the Revenue forecast for this market by the following segments and sub-segments: • By Application: o Oncology Lung Blood Breast Liver Colorectal Prostate Others Cancers o Non-Cancer Applications ( Other Diseases) • Types of Circulating Biomarkers collected and studied to detect diseases: o Circulating Tumour Cells (CTCs) o Extracellular Vesicles (EVs) o Circulating Tumour DNA (ctDNA) o Cell-Free DNA (cfDNA) o Others • End User o Reference Laboratories o Research Centres o Hospitals and Physician Laboratories o Academic Centres o Other End Users • Geography o North America USA Canada o Asia Pacific China Japan South Korea Australia India Rest of Asia Pacific o Europe UK Germany France Sweden Spain Russia o Middle East and Africa GCC Countries Israel Rest of Middle-east and Africa o Latin America Brazil Argentina Rest of Latin America
Table of Contents
Global Liquid Biopsy Market1. Introduction 1.1 Objectives of the Study 1.2 Market Definition 1.3 Market Scope 1.3.1 Markets Covered 1.3.2 Years Considered for the Study 1.4 Currency 1.5 Limitations 1.6 Stakeholders 2. Research Methodology 2.1 Research Approach 2.1.1 Secondary Data 18.104.22.168 Secondary Sources 2.1.2 Primary Data 22.214.171.124 Primary Sources 126.96.36.199 Key Industry Insights 2.2 Market Size Estimation 2.3 Market Breakdown and Data Triangulation 2.4 Assumptions for the Study 3. Executive Summary 4. Premium Insights 4.1 Liquid Biopsy Market: Overview 4.2 Global Market: By Clinical Application 4.3 Global Market: Geographic Opportunities and Growth 4.4 Global Market: Geographic Mix 4.5 Global Market: Established and Emerging Markets 4.6. Global liquid biopsy Market Industry Trends 5. Market Overview 5.1 Introduction 5.2 Market Dynamics 5.2.1 Drivers 188.8.131.52 Increasing Prevalence of Cancer 184.108.40.206 Increasing Preference and demand for safe and Non-invasive Procedures 220.127.116.11 Initiatives Undertaken By Government and Global Health Organizations 18.104.22.168 Technological Advancement to Augment Market Revenues 22.214.171.124 Rising Emphasis on Personalized Medicine 126.96.36.199 Availability of Funding for Liquid Biopsy R&D 5.2.2 Restraints 188.8.131.52 Low Sensitivity and Specificity 184.108.40.206 Limitations associated with liquid biopsy testing 220.127.116.11 Lack of awareness in developing and underdeveloped regions 5.2.3 Opportunities 18.104.22.168 Growing Interest in Liquid Biopsy and the Potential of its emerging markets 22.214.171.124 Use of liquid biopsy for treatment of rare cancer 5.2.4 Challenges 126.96.36.199 Unclear Regulatory and Reimbursement Scenario 6. Global Liquid Biopsy Market, By Product and Service 6.1 Introduction 6.2 Assay Kits and Reagents 6.3 Instruments and Platforms 6.4 Services 7. Global Liquid Biopsy Market, By Circulating Biomarker 7.1 Introduction 7.2 Circulating Tumour Cells 7.3 Circulating Tumour DNA (CTDNA) 7.4 Cell-Free DNA 7.5 Extracellular Vesicles (Evs) 7.6 Other Circulating Biomarkers 8. Global Liquid Biopsy Market, By Clinical Application 8.1 Introduction 8.2 Early Cancer Screening 8.3 Therapy Selection 8.4 Treatment Monitoring 8.5 Recurrence Monitoring 9. Global Liquid Biopsy Market, By Application 9.1 Introduction 9.2 Cancer Applications 9.2.1 Lung Cancer 9.2.2 Breast Cancer 9.2.3 Colorectal Cancer 9.2.4 Prostate Cancer 9.2.5 Liver Cancer 9.2.6 Other Cancers 9.3 Non-Cancer Applications 10. Global Liquid Biopsy Market, By End User 10.1 Introduction 10.2 Reference Laboratories 10.3 Hospitals and Physician Laboratories 10.4 Academic and Research Centres 10.5 Other End Users 11. Global Liquid Biopsy Market, By Geography 11.1 Introduction 11.2 North America 11.2.1 US 11.2.2 Canada 11.3 Europe 11.3.1 UK 11.3.2 Germany 11.3.3 France 11.3.4 Italy 11.3.5 Sweden 11.3.6 Spain 11.3.7 Russia 11.4 Asia Pacific 11.4.1 Japan 11.4.2 China 11.4.3 India 11.4.4 South Korea 11.4.5 Australia 11.4.6 Rest of Asia Pacific 11.5 Middle East and Africa 11.5.1 GCC Countries 11.5.2 Israel 11.5.3 Rest of Middle East and Africa 11.6 Latin America 11.6.1 Brazil 11.6.2 Argentina 11.6.3 Rest of Latin America 12. Competitive Landscape 12.1 Market Ranking Analysis 13. Company Profiles 13.1 Biocept, Inc. 13.2 Qiagen N.V. 13.3 Roche Diagnostics 13.4 Bio-Rad Laboratories, Inc. 13.5 Myriad Genetics, Inc. 13.6 Menarini-Silicon Biosystems 13.7 Trovagene, Inc. 13.8 Guardant Health, Inc. 13.9 Mdxhealth SA 13.10 Genomic Health, Inc. 13.11 Raindance Technologies, Inc. 13.12 Thermo Fisher Scientific Inc. 13.13 Illumina, Inc. 13.14 F. Hoffmann-La Roche AG 13.15 Janssen Diagnostics 13.16 GRAIL 13.17 Foundation Medicine